Changes in treatment outcomes of multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 5, 2015, Pages 525-530

  Kwak, N ^a   Kim, H R ^b   Yoo, C G ^a   Kim, Y W ^a   Han, S K ^a   Yim, J J ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Fluoroquinolone; Linezolid; Surgery

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; KANAMYCIN; LINEZOLID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DEATH; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EYE TOXICITY; FEMALE; GASTROINTESTINAL DISEASE; HEARING DISORDER; HEMATOLOGIC DISEASE; HUMAN; HYPOTHYROIDISM; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NEUROLOGIC DISEASE; OTOTOXICITY; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; SEIZURE; SOUTH KOREA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; COHORT ANALYSIS; DRUG EFFECTS; EVALUATION STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FOLLOW UP; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONPARAMETRIC TEST; RECURRENT DISEASE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNIVERSITY HOSPITAL;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84928883927     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0739     Document Type: Article

References (27)

1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. Kang Y, Choi Y J, Cho Y J, et al. Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology 2006; 11: 793-798.
3. White V, Moore-Gillon J. Resource implications of patients with multidrug-resistant tuberculosis. Thorax 2000; 55: 962-963.
4. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
5. van der Werf M, Ködmön C, Hollo V, Sandgren A, Zucs P. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012. Euro Surveill 2014; 19: 20733.
6. Falzon D, Gandhi N, Migliori G B, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
7. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
8. Kim H-R, Hwang S S, Kim H J, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
9. Crofton S J, Chaulet P, Maher D et al. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210. Geneva, Switzerland: World Health Organization, 1997.
10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
11. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva, Switzerland: WHO, 2011.
12. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug-resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS MED 2012; 9: e1001300.
13. Lee M, Lee J, Carroll M W, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Eng J Med 2012; 367: 1508-1518.
14. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
15. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and metaanalysis [Review article]. Int J Tuberc Lung Dis 2012; 16: 447-454.
16. World Health Organization. Definitions and reporting framework for tuberculosis. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO, 2013.
17. Kim H, Lee C, Shin S, et al. The impact of nutritional deficit on mortality of in-patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2010; 14: 79-85.
18. Matos E, Moreira Lemos A. Association between serum albumin levels and in-hospital deaths due to tuberculosis. Int J Tuberc Lung Dis 2006; 10: 1360-1366.
19. Dai G, McMurray D N. Altered cytokine production and impaired antimycobacterial immunity in protein-malnourished guinea pigs. Infect Immun 1998; 66: 3562-3568.
20. Mainali E S, McMurray D N. Protein deficiency induces alterations in the distribution of T-cell subsets in experimental pulmonary tuberculosis. Infect Immun 1998; 66: 927-931.
21. Johnston J C, Shahidi N C, Sadatsafavi M, FitzGerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 2009; 4: e6914.
22. Kim D H, Kim H J, Park S-K, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 113-119.
23. Bastos M L, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-and extensive drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-1374.
24. Hwang S, Kim H, Kim H, et al. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J 2009; 33: 581-585.
25. Yew W W, Chan C K, Leung C C, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481.
26. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
27. Lee J, Lee C-H, Kim D K, et al. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med 2011; 26: 153-159.